Valuation : Laboratorio Reig Jofre SA

Market Cap 221M 257M 208M 190M 356M 24.3B 357M 2.46B 955M 12.47B 966M 945M 40.16B P/E 2026 *
13.6x
P/E 2027 * 22.7x
Enterprise Value 306M 356M 288M 263M 492M 33.59B 494M 3.4B 1.32B 17.23B 1.34B 1.31B 55.52B EV / Sales 2026 *
0.84x
EV / Sales 2027 * 0.77x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2006
Director of Finance/CFO - 20/12/2023
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Chairman - 31/12/2014
Director/Board Member 58 31/12/2014
Director/Board Member - 07/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.99%+1.09%+28.30%+51.13% 408.71B
Weighted average by Cap. -1.10%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 365M 424M 343M 314M 587M 40.04B 588M 4.06B 1.57B 20.54B 1.59B 1.56B 66.18B 392M 455M 369M 337M 630M 43B 632M 4.36B 1.69B 22.06B 1.71B 1.67B 71.07B
Net income 16.7M 19.41M 15.71M 14.35M 26.85M 1.83B 26.92M 186M 72.05M 940M 72.88M 71.29M 3.03B 9.5M 11.04M 8.94M 8.17M 15.27M 1.04B 15.32M 106M 40.99M 535M 41.46M 40.55M 1.72B
Net Debt 84.7M 98.43M 79.69M 72.8M 136M 9.29B 137M 942M 365M 4.77B 370M 362M 15.36B 78.7M 91.46M 74.05M 67.64M 127M 8.64B 127M 875M 340M 4.43B 343M 336M 14.27B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-